Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192099 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension for GLYX13-C-202, NCT01684163
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02192099: Clinical Trial Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT02192099 is a Phase 2 study that was terminated before completion, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02192099, a Phase 2 study, was terminated before completion, sponsored by Naurex, Inc, an affiliate of Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period.
Interventions
- DRUG Rapastinel (225 mg/450 mg IV administration)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-09-08 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 2 |
Why NCT02192099 stopped before completion
NCT02192099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 1 intervention - of which Rapastinel (225 mg/450 mg IV administration) is the first listed.
NCT02192099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02192099 about?
NCT02192099 is a clinical study titled "Open Label Extension for GLYX13-C-202, NCT01684163". Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
What is the current status of trial NCT02192099?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-09-08. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02192099?
The interventions under investigation include: Rapastinel (225 mg/450 mg IV administration) (DRUG).
Who is sponsoring clinical trial NCT02192099?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02192099's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI